

Sabine Heublein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4945598/publications.pdf>

Version: 2024-02-01

42
papers

736
citations

430442

18
h-index

580395

25
g-index

43
all docs

43
docs citations

43
times ranked

1052
citing authors

#	ARTICLE	IF	CITATIONS
1	Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. <i>BMC Cancer</i> , 2012, 12, 553.	1.1	72
2	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5400-5410.	3.2	41
3	The G-Protein Coupled Estrogen Receptor (GPER/GPR30) is a Gonadotropin Receptor Dependent Positive Prognosticator in Ovarian Carcinoma Patients. <i>PLoS ONE</i> , 2013, 8, e71791.	1.1	41
4	The G-Protein-Coupled Estrogen Receptor (GPER) is Expressed in Normal Human Ovaries and is Upregulated in Ovarian Endometriosis and Pelvic Inflammatory Disease Involving the Ovary. <i>Reproductive Sciences</i> , 2012, 19, 1197-1204.	1.1	37
5	Endometrial hyperplasia as a risk factor of endometrial cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 407-421.	0.8	37
6	Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients. <i>BMC Research Notes</i> , 2012, 5, 551.	0.6	32
7	Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways. <i>PLoS ONE</i> , 2015, 10, e0127072.	1.1	32
8	Inducers of G-protein coupled estrogen receptor (GPER) in endometriosis: potential implications for macrophages and follicle maturation. <i>Journal of Reproductive Immunology</i> , 2013, 97, 95-103.	0.8	28
9	The G-Protein-Coupled Estrogen Receptor (GPER/GPR30) in Ovarian Granulosa Cell Tumors. <i>International Journal of Molecular Sciences</i> , 2014, 15, 15161-15172.	1.8	27
10	The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 13-19.	1.2	27
11	Time trends of neoadjuvant chemotherapy for early breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 3049-3058.	2.3	26
12	Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor β are overexpressed in BRCA1 mutated breast cancer and predict prognosis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 57.	3.5	24
13	M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis. <i>Cells</i> , 2020, 9, 1224.	1.8	24
14	Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer. <i>BMC Cancer</i> , 2013, 13, 616.	1.1	21
15	Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer. <i>BMC Cancer</i> , 2018, 18, 201.	1.1	21
16	Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients. <i>BMC Cancer</i> , 2012, 12, 600.	1.1	19
17	Multicentric and multifocal versus unifocal breast cancer: differences in the expression of E-cadherin suggest differences in tumor biology. <i>BMC Cancer</i> , 2013, 13, 361.	1.1	19
18	Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. <i>Histology and Histopathology</i> , 2013, 28, 239-44.	0.5	19

#	ARTICLE	IF	CITATIONS
19	Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR). <i>Journal of Ovarian Research</i> , 2013, 6, 6.	1.3	18
20	Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors. <i>BMC Cancer</i> , 2019, 19, 575.	1.1	17
21	Validated biomarker assays confirm that <i>ARID1A</i> loss is confounded with <i>MMR</i> deficiency, <i>CD8</i> ⁺ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. <i>Journal of Pathology</i> , 2022, 256, 388-401.	2.1	15
22	Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX [®] is an independent prognostic marker for breast cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 50.	3.5	14
23	Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 87-97.	1.0	13
24	The G-Protein-Coupled Estrogen Receptor (GPER) Regulates Trimethylation of Histone H3 at Lysine 4 and Represses Migration and Proliferation of Ovarian Cancer Cells In Vitro. <i>Cells</i> , 2021, 10, 619.	1.8	13
25	Significance of the tumor protease cathepsin D for the biology of breast cancer. <i>Histology and Histopathology</i> , 2014, 29, 433-8.	0.5	12
26	G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients. <i>Frontiers in Endocrinology</i> , 2021, 12, 564002.	1.5	11
27	Real-Time qPCR-Based Detection of Circulating Tumor Cells from Blood Samples of Adjuvant Breast Cancer Patients: A Preliminary Study. <i>Breast Care</i> , 2016, 11, 194-198.	0.8	9
28	p53 determines prognostic significance of the carbohydrate stem cell marker TF1 (CD176) in ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1163-1170.	1.2	9
29	Glycosyltransferases as marker genes for the quantitative polymerase chain reaction-based detection of circulating tumour cells from blood samples of patients with breast cancer undergoing adjuvant therapy. <i>Molecular Medicine Reports</i> , 2015, 12, 2933-2938.	1.1	8
30	EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2519-2527.	1.2	8
31	Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1923-1932.	1.2	8
32	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	1.4	8
33	Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 295.	1.8	6
34	Alpha tocopherol transfer protein (α TTP) is expressed in endometrial carcinoma and is correlated with FIGO stage and 5-year survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 773-781.	1.2	4
35	Extracapsular Lymph Node Involvement in Ovarian Carcinoma. <i>Cancers</i> , 2019, 11, 924.	1.7	4
36	Subcellular Distribution of Thyroid Hormone Receptor Beta in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2698.	1.8	3

#	ARTICLE	IF	CITATIONS
37	TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1899-1907.	1.2	2
38	Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2251-2259.	1.2	2
39	Do hospital type or caseload make a difference in chemotherapy treatment patterns for early breast cancer? Results from 104 German institutions, 2008â€“2017. <i>Breast</i> , 2021, 58, 63-71.	0.9	2
40	How to make students satisfied with digital teaching? Investigative results from teaching evaluations in Gynecology and Obstetrics. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 1587-1596.	0.8	1
41	Evaluation of the anti-Thomsenâ€™Friedenreich antibodies Nemo-TF1 and Nemo-TF2 as prognostic markers in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 643-652.	1.1	0
42	Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study. <i>Cancers</i> , 2022, 14, 418.	1.7	0